Shots:
- The US FDA has approved label expansion of Jaypirca (pirtobrutinib; 100 & 50mg) for the treatment of adults with r/r CLL/SLL who were previously treated with a covalent BTK inhibitor & converted the accelerated approval of Dec 2023 to a full approval
- Label expansion was based on the P-III (BRUIN CLL-321) study assessing Jaypirca (200mg, QD, PO) vs idelalisib + rituximab (IdelaR) or bendamustine + rituximab (BR) in CLL/SLL pts (n=238)
- Jaypirca, a non-covalent BTK inhibitor, is a highly selective, reversible kinase blocker designed to extend BTK-pathway benefit for r/r CLL/SLL pts previously treated with covalent BTK inhibitors
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: SanegeneBio Collaborates with Eli Lilly to Advance RNAi Therapeutics for Metabolic Diseases
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
